PYC Therapeutics

13 November 2026

POLYCYSTIC KIDNEY DISEASE PROGRAM – ENROLMENT TARGET MET

- **PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available**
- **The Company is progressing a drug candidate (known as PYC-003) that addresses the underlying cause of Polycystic Kidney Disease (PKD) through clinical trials[1]**
- **PYC today announces that it has enrolled the first 24 subjects across cohorts C1 and C2 (1.2 and 2.4 mg/kg doses of PYC-003 respectively) in its Phase 1b repeat dose study of PYC-003 in PKD patients**
- **The Company is consequently on track to realise its objective of reading out on 12-month Total Kidney Volume data across a minimum of 24 patients in the Phase 1b repeat dose study in CY27 to enable progression to a potentially registrational Phase 2/3 trial in CY28[2]**
- **PYC expects to present data from its ongoing Phase 1b multiple dose study of PYC-003 in PKD patients and its associated Open-Label Extension study in CY27**

PERTH, Australia – 13 November 2026

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.


The Company currently has three clinical-stage drug development programs including a drug candidate (known as PYC-003) that addresses the underlying cause of Polycystic Kidney Disease (PKD)[3]. PYC today announces that it has met its interim enrolment target of 24 patients across cohorts C1 (1.2 mg/kg) and C2 (2.4 mg/kg) in the ongoing Phase 1b study of PYC-003 in PKD patients.

Whilst PYC will continue to enrol patients into the Phase 1b study, this enrolment milestone positions the Company on track to realise its objective of reading out on 12-month Total Kidney Volume data across a minimum of 24 patients in CY27 to enable progression to a potentially

[1] Additional details on PYC's Phase 1 study of PYC-003 in ADPKD are available using the clinical trials identifier: NCT06714006
[2] Subject to regulatory alignment on the proposed registrational study requirements, assumed patient drop-out rates and the risks and uncertainties outlined in the Company's ASX disclosures of 2 February 2026
[3] For patients with PKD caused by a mutation in the *PKD1* gene

registrational Phase 2/3 trial in CY28[4] (see **Figure 1** for an overview of the proposed clinical development pathway for PYC-003 in PKD).

Figure 1. Proposed clinical development pathway for PYC-003[5]



Further progression in these ongoing studies is expected to be accompanied by alignment with relevant regulatory authorities on the initiation of a registrational combined Phase 2/3 trial aimed at supporting a New Drug Application for PYC-003 in PKD[6].

Next Steps

Data from the ongoing repeat dose studies of PYC-003 (the Phase 1b MAD study and OLE) is expected to be presented in CY27[7].

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development[8].

For more information, visit pyctx.com, or follow us on LinkedIn.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking

[4] Subject to regulatory alignment on the proposed registrational study requirements, assumed patient drop-out rates and the risks and uncertainties outlined in the Company's ASX disclosures of 2 February 2026
[5] Additional details on PYC's Phase 1 study of PYC-003 in PKD are available using the clinical trials identifier: NCT06714006
[6] Subject to the risks and uncertainties outlined in the Company's ASX disclosures of 2 February 2026
[7] Subject to the risks and uncertainties outlined in the Company's ASX disclosures of 2 February 2026
[8] Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank https://doi.org/10.1101/2020.11.02.20222232

statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACT US

Investor relations and media contact
investor@pyctx.com